Puregon
Authorised
This medicine is authorised for use in the European Union
follitropin beta
MedicineHumanAuthorised
- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.
If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).
Puregon is a powder and solvent to be made up into a solution for injection. It is also available as a solution for injection in a vial or a cartridge. Puregon contains the active substance follitropin beta.
Puregon is used to treat infertility in women in the following situations:
- women who are anovulatory (do not produce eggs) and do not respond to treatment with clomiphene citrate (another medicine that stimulates ovulation);
- women who are undergoing fertility treatment (assisted reproductive techniques, such as in vitro fertilisation). Puregon is administered to stimulate the ovaries to produce more than one egg at a time.
Puregon can also be used to stimulate sperm production in men who have hypogonadotrophic hypogonadism (a rare hormone deficiency disease).
Puregon can only be obtained with a prescription.
Treatment with Puregon should be carried out by a doctor who has experience in the treatment of fertility problems. Puregon is given as a ‘subcutaneous’ injection (under the skin) or into a muscle. The powder should be mixed with the solvent provided just before use. The patient or their partner may carry out the injections. Puregon should only be administered by people who have been trained by the doctor and have access to expert advice. The dose and frequency of administration of Puregon depend on its use (see above) and the patient’s response to treatment. For a full description of the doses, please see the package leaflet.
The active substance in Puregon, follitropin beta, is a copy of the natural hormone follicle stimulating hormone (FSH). In the body, FSH regulates the reproductive function: in women, it stimulates the production of eggs, and in men, it stimulates the production of sperm by the testicles. Previously, the FSH used as a medicine was extracted from urine. The follitropin beta in Puregon is produced by a method known as ‘recombinant DNA technology’. It is made by a cell that has received a gene (DNA), which makes it able to produce human FSH.
Puregon’s use in women undergoing fertility treatment has been studied in 981 patients. The number of eggs recovered and the ongoing pregnancy rate were the main measures of effectiveness. Puregon was studied in 172 anovulatory women, measuring how many cycles of treatment were needed for these women to ovulate. In men, Puregon was studied to see its effect on sperm production in 49 patients. In all of the studies, Puregon was compared to the natural FSH hormone that was extracted from urine.
Puregon was as effective as the comparator in all of the studies. Puregon was as effective as urinary FSH as a fertility treatment, in producing ovulation and in producing sperm.
The most common side effects reported are a reaction and pain at the injection site. In 4% of the women treated with Puregon in clinical studies, signs and symptoms related to ovarian hyperstimulation syndrome (e.g. feeling sick, weight gain and diarrhoea) have been reported. Ovarian hyperstimulation syndrome occurs when the ovaries over-respond to treatment. Doctors and patients must be aware of this possibility. For a full list of all side effects reported with Puregon, see the package leaflet.
Puregon should not be used in people who may be hypersensitive (allergic) to follitropin beta or any of the other ingredients. Puregon must not be used in patients with tumours of the ovary, breast, womb, testicle, pituitary gland or hypothalamus. It must not be used in men with testicular failure. In women, it must not be used when there is ovarian failure, ovarian enlargement or the presence of cysts that are not due to polycystic ovarian disease, or vaginal bleeding. For the full list of restrictions, see the package leaflet.
The Committee for Medicinal Products for Human Use (CHMP) decided that Puregon’s benefits are greater than its risks in the female for the treatment of infertility, and in the male for deficient spermatogenesis due to hypogonadotrophic hypogonadism. The Committee recommended that Puregon be given marketing authorisation.
The European Commission granted a marketing authorisation valid throughout the European Union, for Puregon on 3 May 1996. The marketing authorisation holder is N.V. Organon. The marketing authorisation was renewed on 3 May 2001 and on 3 May 2006.
Product information
Latest procedure affecting product information:
PSUSA/00001465/202305
27/03/2024
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Puregon
- Active substance
- follitropin beta
- International non-proprietary name (INN) or common name
- follitropin beta
- Therapeutic area (MeSH)
- Infertility
- Hypogonadism
- Anatomical therapeutic chemical (ATC) code
- G03GA06
Pharmacotherapeutic group
Sex hormones and modulators of the genital systemTherapeutic indication
In the female:
Puregon is indicated for the treatment of female infertility in the following clinical situations:
- anovulation (including polycystic ovarian syndrome, PCOS) in women who have been unresponsive to treatment with clomifene citrate;
- controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programs (e.g. in-vitro fertilisation / embryo transfer (IVF/ET), gamete intrafallopian transfer (GIFT) and intracytoplasmic sperm injection (ICSI)).
In the male:
- Deficient spermatogenesis due to hypogonadotrophic hypogonadism.
Topics
This page was last updated on